Matching Items (2)
Filtering by

Clear all filters

135764-Thumbnail Image.png

Drug Release from in \u2014 situ gelling material

Description
The main goal of this project was to study and understand the release of gentamicin from in – situ, self – reactive drug delivery gelling matrix. The motivation behind this was to create a drug delivery mechanism for gentamicin and eliminate the need for re–injecting the drug multiple times into…

The main goal of this project was to study and understand the release of gentamicin from in – situ, self – reactive drug delivery gelling matrix. The motivation behind this was to create a drug delivery mechanism for gentamicin and eliminate the need for re–injecting the drug multiple times into the patient. Gentamicin is used to treat various different bacterial infections of the central nervous system, blood, kidneys, gall bladder, bile duct, heart cavity linings, and heart valves. Pentaerythritol–tetrakis
(3 – mercaptoproprionate; QT) was crosslinked with poly(ethylene glycol) diacrylate (PEGDA) having an average molecular weight of 575 with the help of Phosphate Buffer Saline (PBS), with a buffer ionic strength of 0.143M and a pH of 8.9 and 11, for the drug concentrations of 5 mg/mL and 50 mg/mL, respectively. The Michael – type reaction formed the crosslinked self – administering gelling matrix. With the gelling matrix starting to coagulate into a hydrophobic solid in about 5 minutes, the material was injected into Tygon tubing. After complete solidification, the drug – loaded gels were extracted from the tubing and divided into 1 cm cylinders. The cylinders with 5mg/mL and 50mg/mL drug concentration exhibited a sustained and controlled release curve for about 288 hours. This project as well as this drug delivery system can in the future be expanded for use in the delivery of more hydrophobic long – term drugs to the patient.
ContributorsJolly, Nehal (Author) / Vernon, Brent (Thesis director) / Herman, Richard (Committee member) / Harrington Bioengineering Program (Contributor) / Barrett, The Honors College (Contributor)
Created2016-05
135590-Thumbnail Image.png

Formulation Development and Evaluation of In-Situ Polymeric Drug Delivery Implants Formed by Tattooing

Description
This study demonstrates that a polymer and drug conjugate can be tattooed onto tissue and deliver drug in a sustained manner. A number of polymers and drugs were investigated in this study in the aims of developing a formulation that could achieve sustained drug delivery for 1-2 weeks. The polymers…

This study demonstrates that a polymer and drug conjugate can be tattooed onto tissue and deliver drug in a sustained manner. A number of polymers and drugs were investigated in this study in the aims of developing a formulation that could achieve sustained drug delivery for 1-2 weeks. The polymers selected for testing were PDLG 5004, PDLLA-Glycerol, and PEG-PLA, and the drugs used in conjunction with these polymers were rifampicin, moxifloxacin, and dexamethasone. Varying formulas containing these polymer and drug combinations were tattooed onto three different tissue types: bovine pericardial tissue, porcine corneal tissue, and porcine sclera tissue. The drug release rates from these tattoos were determined and characterized after studying the release for up to 20 days. The release rate of dexamethasone from both PDLG 5004 and PDLLA-Glycerol when tattooed onto bovine pericardial tissue demonstrated the best release rate of the formulations tested, with up to 14 days of sustained release. This preliminary research into tattoo-based, polymeric drug delivery is promising, and has the possibility to be developed into a beneficial form of ophthalmic drug delivery that could be expanded to other areas of treatment as well.
ContributorsKaplan, Serena Louise (Author) / Vernon, Brent (Thesis director) / Pathak, Chandrashekhar (Committee member) / Harrington Bioengineering Program (Contributor) / Barrett, The Honors College (Contributor)
Created2016-05